Modelling the impact of a combined varicella and zoster vaccination programme on the epidemiology of varicella zoster virus in England

Vaccine

Volumn 29, Issue 13, 2011, Pages 2411-2420

  Van Hoek, Albert Jan ^a   Melegaro, Alessia ^a,b   Zagheni, Emelio ^c   Edmunds, W John ^a,d   Gay, Nigel ^a,b  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b BOCCONI UNIVERSITY   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Chickenpox; Herpes Zoster; Infectious disease modelling; Shingles; Vaccination; Varicella zoster

Indexed keywords

CHICKENPOX VACCINE; PLACEBO; VARICELLA ZOSTER VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CHICKENPOX; CHILD; CHILDHOOD; CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; EPIDEMIOLOGICAL DATA; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; IMMUNITY; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SINGLE DRUG DOSE; TREATMENT OUTCOME; UNITED KINGDOM; VACCINATION; VARICELLA ZOSTER VIRUS; VIRUS TRANSMISSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; ENGLAND; FEMALE; HERPES ZOSTER; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MODELS, STATISTICAL; YOUNG ADULT;

EID: 79952364664     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.01.037     Document Type: Article

References (40)

1. Recommendations for the use of live attenuated varicella vaccine. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 1995, 95(5):791-796.
2. Prevention of varicella. Update recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1999, 48(RR-6):1-5.
3. Marin M., Guris D., Chaves S.S., Schmid S., Seward J.F. Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007, 56(RR-4):1-40.
4. Brisson M., Melkonyan G., Drolet M., De Serres G., Thibault R., De Wals P. Modeling the impact of one- and two-dose varicella vaccination on the epidemiology of varicella and zoster. Vaccine 2010, 28:3385-3397.
5. Rimland D., Moanna A Increasing incidence of Herpes Zoster among Veterans. Clin Infect Dis 2010, 50(April (7)):1000-1005.
6. Carville K.S., Riddell M.A., Kelly H.A. A decline in Varicella but an uncertain impact on zoster following Varicella vaccination in Victoria, Australia. Vaccine 2010, 28(13):2532-2538.
7. Donahue J.G., Kieke B.A., Gargiullo P.M., Jumaan A.O., Berger N.R., McCauley J.S., et al. Herpes Zoster and exposure to the Varicella Zoster virus in an era of Varicella vaccination. Am J Public Health 2010, 100:1116-1122.
8. Hope-Simpson R.E. The nature of Herpes Zoster: a long-term study and a new hypothesis. Proc R Soc Med 1965, 58:9-12.
9. Brisson M., Gay N.J., Edmunds W.J., Andrews N.J. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002, 20(19-20):2500-2507.
10. Thomas S.L., Wheeler J.G., Hall A.J. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002, 360(9334):678-682.
11. Brisson M., Edmunds W.J., Gay N.J., Law B., De Serres G. Modelling the impact of immunization on the epidemiology of varicella zoster virus. Epidemiol Infect 2000, 125(3):651-669.
12. Schuette M.C., Hethcote H.W. Modeling the effects of varicella vaccination programs on the incidence of chickenpox and shingles. Bull Math Biol 1999, 61:1031-1064.
13. Harpaz R., Ortega-Sanchez I.R., Seward J.F. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30.
14. Oxman M.N., Levin M.J., Johnson G.R., Schmader K.E., Straus S.E., Gelb L.D., et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 2005, 352(22):2271-2284.
15. Halloran M.E., Cochi S.L., Lieu T.A., Wharton M., Fehrs L. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994, 140(July (2)):81-104.
16. Brisson M., Edmunds W.J., Gay N.J. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003, 70(Suppl. 1):S31-S37.
17. Michalik D.E., Steinberg S.P., Larussa P.S., Edwards K.M., Wright P.F., Arvin A.M., et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008, 197(April (7)):944-949.
18. Brisson M., Edmunds W.J., Gay N.J., Law B., De Serres G. Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of vaccination programmes. Vaccine 2000, 18(25):2775-2778.
19. Lopez A.S., Guris D., Zimmerman L., Gladden L., Moore T., Haselow D.T., et al. One dose of varicella vaccine does not prevent school outbreaks: is it time for a second dose?. Pediatrics 2006, 117(6):e1070-e1077.
20. American Academy of Pediatrics Committee on Infectious Diseases Prevention of varicella recommendations for use of varicella vaccines in children including a recommendation for a 2-dose varicella immunization schedule. Pediatrics 2007, 120(July (1)):221-231.
21. Thiry N., Beutels P., Van Damme P., Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003, 21(1):13-38.
22. Rozenbaum M.H., van Hoek A.J., Vegter S., Postma M.J. Cost-effectiveness of varicella vaccination programs: an update of the literature. Expert Rev Vaccines 2008, 7(August (6)):753-782.
23. Karhunen M., Leino T., Salo H., Davidkin I., Kilpi T., Auranen K. Modelling the impact of varicella vaccination on varicella and zoster. Epidemiol Infect 2010, 138(4):469-481.
24. Gao Z., Gidding H.F., Wood J.G., MacIntyre Modeling the impact of one-dose vs. two-dose vaccination regimens on the epidemiology of varicella zoster virus in Australia. Epidemiol Infect 2010, 138(4):457-468.
25. Brisson M., Edmunds W.J. Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 2003, 88(10):862-869.
26. Mossong J., Hens N., Jit M., Beutels P., Auranen K., Mikolajczyk R., et al. Social contacts and mixing patterns relevant to the spread of infectious diseases. PloS Med 2008, 5(3):e74.
27. Gershon A.A., LaRussa P., Steinberg S., Mervish N., Lo S.H., Meier P. The protective effect of immunologic boosting against zoster: an analysis in leukemic children who were vaccinated against chickenpox. J Infect Dis 1996, 173(February (2)):450-453.
28. Gershon A.A., Takahashi, Seward J. Varicella vaccine. Vaccines. 2004, Saunders, Philadelphia, PA. 4th ed. S.A. Plotkin, W.A. Orenstein (Eds.).
29. Hambleton S., Steinberg S.P., LaRussa P.S., Shapiro E.D., Gershon A.A. Risk of Herpes Zoster in adults immunized with varicella vaccine. J Infect Dis 2008, 197:S196-S199.
30. Wallinga J., Teunis P., Kretzschmar M. Using data on social contacts to estimate age-specific transmission parameters for respiratory-spread infectious agents. Am J Epidemiol 2006, 164(10):936-944.
31. Nardone A., de Ory F., Carton M., Cohen D., van Damme P., Davidkin I., et al. The comparative sero-epidemiology of varicella zoster virus in 11 countries in the European region. Vaccine 2007, 25(November (45)):7866-7872.
32. McCormick A., Fleming D.M., Charlton J. Morbidity statistics from General Practice, fourth national study 1991-1992: MSGP4. Series MB5:3 1995, HMSO, London, p. 1-36.
33. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pedietr Infect Dis J 2004, 23(February (2)):132-137.
34. van Hoek A.J., Gay N., Opstelten W., Edmunds W.J. Estimating the cost-effectiveness of vaccination against Herpes Zoster in England and Wales. Vaccine 2009, 27(9):1454-1467.
35. Joint Committee on Vaccination and Immunisation (JCVI) JCVI short statement on Herpes zoster vaccines 2010, Joint Committee on Vaccination and Immunisation, London.
36. Yawn B.P., Saddier P., Wollan P.C., St Sauver J.L., Kurland M.J., Sy L.S. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc 2007, 82(November (11)):1341-1349.
37. Mullooly J.P., Riedlinger K., Chun C., Weinmann S., Houston H. Incidence of herpes zoster 1997-2002. Epidemiol Infect 2005, 133:245-253.
38. Yih W.K., Brooks D.R., Lett S.M., Jumaan A.O., Zhang Z., Clements K.M., et al. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998-2003. BMC Public Health 2005, 5(June):68.
39. Jumaan A.O., Yu O., Jackson L.A., Bohlke K., Galil K., Seward J.F. Incidence of herpes zoster, before and after varicella-vaccination-associated decreases in the incidence of varicella, 1992-2002. J Infect Dis 2005, 191(June (12)):2002-2007.
40. Reynolds M.A., Chaves S.S., Harpaz R., Lopez A.S., Seward J.F. The impact of the varicella vaccination program on herpes zoster epidemiology in the United States: a review. J Infect Dis 2008, 197(March (Suppl. 2)):S224-S227.